2730 Sidney Street, Ste. 300
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.
Leadership: Jonathan Steckbeck (CEO & Founder)
17 articles with Peptilogics
Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
Peptilogics today announced that the company received an award from the Cystic Fibrosis Foundation.
Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection
Peptilogics today announced two studies on its lead designed peptide therapeutic, PLG0206, an investigational drug, have been published in peer-reviewed journals Antimicrobial Agents and Chemotherapy (AAC) and Microbiology Spectrum.
Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021
Peptilogics today presented Phase 1 safety and tolerability data on PLG0206, a unique engineered antibacterial peptide being developed for the treatment of prosthetic joint infection (PJI).
Peptilogics will present first-in-human Phase 1 data on its lead investigational therapy PLG0206
7/30/2021Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.
Peptilogics announced the appointments of Nikhil Bhide as Chief Business Officer, Dr. Marc Lesnick as SVP Regulatory & Quality, Jodie GiIlon as SVP Corporate Affairs & Patient Advocacy, Albert Fonticiella as VP of People, and Steve Kulp as VP of Operations.
Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy
Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, today announced the completion of a Phase 1 clinical trial for its lead compound PLG0206
3/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
- Dr. David Huang, leader in anti-infective drug development, to serve as SVP, Chief Medical Officer - Dr. Nick Nystrom, global leader in life sciences AI, to serve as SVP, Computing & Data - Nicholas Pachuda, seasoned expert in business strategy, to serve as SVP, Portfolio Strategy & Development
12/23/2020A roundup of the latest biopharma companies scooping up cash through IPOs and financing rounds.
Peptilogics Closes $35.4 Million Series B Financing to Further Advance Proprietary Computational Peptide Drug Design and Discovery Platform
Peptilogics announced today the closing of a $35.4 million Series B financing. The financing was led by Presight Capital, with participation from a new investor syndicate including Founders Fund as w
Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections
Peptilogics announced that the US Food and Drug Administration has granted Orphan Drug Designation for PLG0206, the company's first-in-class, broad-spectrum antibiotic peptide, for the treatment of prosthetic joint infections, a rare life-threatening condition that may result from arthroplasty or joint replacement procedures.
CARB-X funds Peptilogics to develop a new class of antibiotics to treat serious superbug infections associated with implants
Peptilogics’ engineered cationic antibiotic peptide is designed to kill multi-drug-resistant bacteria rapidly, transforming the way prosthetic joint infections (PJI) are treated
Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206
Therapeutic Development to Address Potential Orphan Indication and Global Pandemic
Peptilogics Completes Successful Pre-IND Meeting With the Food and Drug Administration (FDA) for PLG0206 in Prosthetic Joint Infections (PJI)
Peptilogics today announced it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of PLG0206 for the treatment of prosthetic joint infections (PJI).
Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
Builds on PLG0206 studies published in Nature Scientific Reports.
Peptilogics Set To Transform The Development Of Antibiotics For The Treatment Of Multidrug-Resistant Bacterial Infections With Major Backing From Peter Thiel